Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

ANI Pharmaceuticals, Inc. - Common Stock (NQ:ANIP)

79.26 +1.90 (+2.46%)
Streaming Delayed Price Updated: 11:17 AM EST, Feb 17, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about ANI Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 Next >
News headline image
Delaware Superior Court Jury Issues Unanimous Verdict that CG Oncology Owes No Future Royalties or Other Payments to ANI Pharmaceuticals
From CG Oncology Inc.
Via GlobeNewswire
News headline image
ANI Pharmaceuticals and Alimera Sciences Announce Closing Date of Merger
From ANI Pharmaceuticals, Inc. and Alimera Sciences, Inc.
Via Business Wire
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Morphic Holding, Inc. (Nasdaq - MORF), Desktop Metal, Inc. (NYSE - DM), Alimera Sciences, Inc. (Nasdaq - ALIM), Avangrid, Inc. (NYSE - AGR)
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Alimera Sciences, Inc. (Nasdaq - ALIM), Avangrid, Inc. (NYSE - AGR), PlayAGS, Incorporated (NYSE - AGS), RBAZ Bancorp, Inc. (OTCPK - RBAZ)
From Brodsky & Smith LLC
Via GlobeNewswire
ANI Pharmaceuticals Inc. (NASDAQ: ANIP) Records 52-Week High Wednesday Morning
Via Investor Brand Network
News headline image
ANI Pharmaceuticals to Present at the Jefferies Healthcare Conference
From ANI Pharmaceuticals, Inc.
Via Business Wire
News headline image
ANI Pharmaceuticals Announces Closing of Public Offering of Common Stock Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
From ANI Pharmaceuticals, Inc.
Via Business Wire
News headline image
ANI Pharmaceuticals Announces FDA Approval and Commercialization of Two ANDAs with CGT Exclusivity
From ANI Pharmaceuticals, Inc.
Via Business Wire
News headline image
ANI Pharmaceuticals Announces Pricing of $75 Million Public Offering of Common Stock
From ANI Pharmaceuticals, Inc.
Via Business Wire
News headline image
ANI Pharmaceuticals Announces Proposed Public Offering of Common Stock
From ANI Pharmaceuticals, Inc.
Via Business Wire
News headline image
ANI Pharmaceuticals Reports Record First Quarter 2023 Financial Results and Raises Full-Year 2023 Guidance
From ANI Pharmaceuticals, Inc.
Via Business Wire
News headline image
ANI Pharmaceuticals to Discuss First Quarter 2023 Financial Results on May 8, 2023, at 8:30 a.m. ET
From ANI Pharmaceuticals, Inc.
Via Business Wire
News headline image
ANI Pharmaceuticals to Present at the H.C. Wainwright BioConnect Investor Conference at NASDAQ
From ANI Pharmaceuticals, Inc.
Via Business Wire
News headline image
ANI Pharmaceuticals Announces the FDA Approval and Launch of Nitrofurantoin Oral Suspension USP
From ANI Pharmaceuticals, Inc.
Via Business Wire
News headline image
ANI Pharmaceuticals Announces the FDA Approval of Colestipol Hydrochloride Tablets USP
From ANI Pharmaceuticals, Inc.
Via Business Wire
News headline image
ANI Pharmaceuticals Reports Record Fourth Quarter Financial Results and Achieves Full Year 2022 Revenue Milestone; Initiates 2023 Guidance
From ANI Pharmaceuticals, Inc.
Via Business Wire
News headline image
ANI Pharmaceuticals to Discuss Fourth Quarter and Full Year 2022 Financial Results on March 9, 2023, at 8:30 a.m. ET
From ANI Pharmaceuticals, Inc.
Via Business Wire
News headline image
ANI Pharmaceuticals Announces the FDA Approval and Launch of Levocarnitine Tablets USP
From ANI Pharmaceuticals, Inc.
Via Business Wire
News headline image
ANI Pharmaceuticals Announces the FDA Approval and Launch of Fluoxetine Oral Solution USP
From ANI Pharmaceuticals, Inc.
Via Business Wire
News headline image
ANI Pharmaceuticals Announces the FDA Approval and Launch of Trimethoprim Tablets USP
From ANI Pharmaceuticals, Inc.
Via Business Wire
News headline image
ANI Pharmaceuticals Reports Third Quarter 2022 Financial Results; Reports Record Net Revenues
From ANI Pharmaceuticals, Inc.
Via Business Wire
News headline image
ANI Pharmaceuticals to Discuss Third Quarter 2022 Financial Results on November 9, 2022, at 8:00 a.m. ET
From ANI Pharmaceuticals, Inc.
Via Business Wire
News headline image
ANI Pharmaceuticals Appoints Krista Davis as Chief Human Resources Officer
From ANI Pharmaceuticals, Inc.
Via Business Wire
News headline image
ANI Pharmaceuticals to Present at the H.C. Wainwright 24th Annual Global Investment Conference
From ANI Pharmaceuticals, Inc.
Via Business Wire
News headline image
ANI Pharmaceuticals Announces the Launch of Prochlorperazine Maleate Tablets USP
From ANI Pharmaceuticals, Inc.
Via Business Wire
News headline image
ANI Pharmaceuticals Announces FDA Approval and Imminent Launch of Dexamethasone Tablets USP
From ANI Pharmaceuticals, Inc.
Via Business Wire
News headline image
ANI Pharmaceuticals Reports Second Quarter 2022 Financial Results; Reports Record Net Revenues and Raises Full-Year 2022 Net Revenue Guidance for Purified Cortrophin® Gel
From ANI Pharmaceuticals, Inc.
Via Business Wire
News headline image
ANI Pharmaceuticals Announces the Launch of Acebutolol Hydrochloride Capsules USP
From ANI Pharmaceuticals, Inc.
Via Business Wire
News headline image
ANI Pharmaceuticals Acquires ANDAs from Oakrum Pharma, LLC
From ANI Pharmaceuticals, Inc.
Via Business Wire
News headline image
ANI Pharmaceuticals to Discuss Second Quarter 2022 Financial Results on August 8, 2022, at 8:00 a.m. ET
From ANI Pharmaceuticals, Inc.
Via Business Wire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.